InspireMD outlines FDA submission before year’s end as TCAR approval adds ~40,000 annual procedures

• “The third quarter marked a turning point for InspireMD,” and the company “announced a proposed underwritten equity public offering” that management said is “intended to support the next phase of our growth, including the full commercialization

Seeking Alpha's Disclaimer: This article was automatically generated by an AI tool based on content available on the Seeking Alpha website, and has not been curated or reviewed by humans. Due to inherent limitations in using AI-based tools, the accuracy, completeness, or timeliness of such articles cannot be guaranteed. This article is intended for informational purposes only. Seeking Alpha does not take account of your objectives or your financial situation and does not offer any personalized investment advice. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank.